Apelin: A New Heart-Lung Peptide Biomarker Complementing BNP

Apelin, a novel peptide, was identified as a plasma marker of cardiopulmonary disease, with levels distinguishing cardiac from respiratory causes of symptoms and complementing natriuretic peptide testing.

Goetze, Jens Peter et al.·Regulatory peptides·2006·Moderate EvidenceCross-Sectional
RPEP-01141Cross SectionalModerate Evidence2006RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Cross-Sectional
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Plasma apelin levels differentiated between cardiac and pulmonary disease causes and provided complementary prognostic information alongside natriuretic peptides — a new peptide biomarker for cardiopulmonary disease characterization.

Key Numbers

How They Did This

cross-sectional study on neuropeptides, natriuretic-peptides.

Why This Research Matters

Relevant for neuropeptides, natriuretic-peptides, cardiovascular, respiratory.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Plasma apelin levels differentiated between cardiac and pulmonary disease causes and provided complementary prognostic information alongside natriuret
Evidence Grade:
moderate evidence.
Study Age:
Published in 2006.
Original Title:
Apelin: a new plasma marker of cardiopulmonary disease.
Published In:
Regulatory peptides, 133(1-3), 134-8 (2006)
Database ID:
RPEP-01141

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

A snapshot of a population at one point in time.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Apelin: A New Heart-Lung Peptide Biomarker Complementing BNP

What was found?

Apelin, a novel peptide, was identified as a plasma marker of cardiopulmonary disease, with levels distinguishing cardiac from respiratory causes of symptoms and complementing natriuretic peptide testing.

Read More on RethinkPeptides

Cite This Study

RPEP-01141·https://rethinkpeptides.com/research/RPEP-01141

APA

Goetze, Jens Peter; Rehfeld, Jens F; Carlsen, Jørn; Videbaek, Regitze; Andersen, Claus B; Boesgaard, Soeren; Friis-Hansen, Lennart. (2006). Apelin: a new plasma marker of cardiopulmonary disease.. Regulatory peptides, 133(1-3), 134-8.

MLA

Goetze, Jens Peter, et al. "Apelin: a new plasma marker of cardiopulmonary disease.." Regulatory peptides, 2006.

RethinkPeptides

RethinkPeptides Research Database. "Apelin: a new plasma marker of cardiopulmonary disease." RPEP-01141. Retrieved from https://rethinkpeptides.com/research/goetze-2006-apelin-a-new-plasma

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.